Rheumatoid arthritis (RA) is often characterized by bone loss and fragility fractures and is a
frequent comorbidity. Compared with a matched population, RA patients with fractures have …

Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …

Idiopathic pulmonary fibrosis (IPF) is a devastating, progressive and ultimately fatal lung
disease. The combination of poor prognosis, uncertainty of disease course and severe …

600 patients aged≥ 18 years will be randomised in a 1: 1 ratio to nintedanib or placebo.
Patients with diagnosis of IPF will be excluded. The study population will be enriched with …

Background In fibrotic interstitial lung diseases, exertional breathlessness is strongly linked
to health-related quality of life (HRQOL). Breathlessness is often associated with oxygen …

Background: In the past two decades, many advances have been made to our
understanding of interstitial lung disease (ILD) and the way we approach its treatment …

Background Rituximab is often used as rescue therapy in interstitial lung disease (ILD)
associated with connective tissue disease (CTD), but has not been studied in clinical trials …

Background Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and
is difficult to treat. PA101 is a novel formulation of sodium cromoglicate delivered via a high …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity
and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung …

Health-related quality of life or health status is significantly impaired in bronchiectasis. There
is a paucity of brief, simple-to-use, disease-specific health status measures. The aim of this …